-+ 0.00%
-+ 0.00%
-+ 0.00%

Summit Therapeutics Q3 Adj. EPS $(0.20) Beats $(0.28) Estimate

Benzinga·11/04/2026 22:00:49
Listen to the news
Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.28) by 28.57 percent. This is a 53.85 percent decrease over losses of $(0.13) per share from the same period last year.